Symbols

DMRA

Damora Therapeutics·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DMRA

Damora Therapeutics, Inc.

An innovative biotechnology company focused on redefining treatment options for patients with hematologic disorders

Industry

Pharmaceutical

Established Date

Listing Date

10/29/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.damoratx.com

Security Type

Common stock

Office address

221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453

Business

Introduction

Damora Therapeutics, Inc., incorporated in Delaware in October 2019, is an innovative biotechnology company focused on redefining treatment options for patients with hematological disorders. The company is advancing the development of a new generation of biologics aimed at treating myeloproliferative tumors driven by mutant calreticulin, including primary thrombocytosis and myelofibrosis, which urgently need treatment options that can improve the condition. Several of Damora's projects demonstrate best-in-class potential and are scheduled to enter clinical development in 2026. The company's goal is to rapidly roll out optimized therapies that not only cover a wide range of mutation types, but are also extremely easy to use, with the ultimate goal of significantly improving patient outcomes.

Company Financials

EPS

DMRA has released its 2025 Q3 earnings. EPS was reported at -2.36, versus the expected 0, missing expectations. The chart below visualizes how DMRA has performed over recent quarters, highlighting trends in earnings surprises.